Associate or full Professor WOT, Department of Pediatrics, Center of Respiratory Biology and Therapeutics

The Department of Pediatrics at the University of Washington School of Medicine in partnership with Seattle Childrens Hospital are seeking a full-time or at a minimum 0.75 part-time faculty member at the rank of Associate Professor without tenure by reason of funding or full Professor without tenure by reason of funding on the faculty-scientist track. Successful candidates will be expected to generate additional funding through clinical activities. This individual will have the role of Clinical Studies Medical Director of the Cystic Fibrosis Therapeutics Development Network Coordinating Center (CF TDNCC) at Seattle Childrens Research Institute in the Center of Respiratory Biology and Therapeutics.

The successful candidate will be expected to engage in basic and translational research as well as study design and clinical outcomes research.

Please be advised that part-time positions are not eligible for visa sponsorship or permanent residence sponsorship by the University of Washington.

The base salary range for this position will be: Associate Professors $18500 - $26662 per month ($222000- $319944 annually) Professors $22334 - $34167 per month ($268008 - $410004 annually) commensurate with experience and qualifications or as mandated by a U.S. Department of Labor prevailing wage determination. This range is inclusive of base salary provided through the Childrens University Medical Group (CUMG) practice plan in addition to base salary provided by the University. Please note that only compensation provided by the University is included in University benefit determinations and calculations. Compensation provided by Childrens University Medical Group (CUMG) practice plan may provide eligibility for separate benefits offered by that organization.

Other compensation associated with this position may include incentive through Childrens University Medical Group practice plan. Additional administrative responsibilities may be offered to a specific candidate with appropriate experience and qualifications which may result in an administrative supplement (ADS).

Associate and full Professors hold indefinite appointments that align with a 12-month service period (July 1-June 30). Faculty with 12-month service periods are paid for 11 months of service over a 12-month period (July-June) meaning the equivalent of one month is available for paid time off.

All University of Washington faculty engage in teaching research and service.

Anticipated start date is Summer 2025.

Responsibilities

CF TDNCC Clinical Studies Medical Director provides direction of and will run the Medical Monitoring program supporting multicenter CF studies coordinated through the CF TDNCC with responsibilities including assisting with back up for core medical monitor team reviewing safety reporting providing advice for challenging adverse event reports and interpretation of those events running annual medical monitor training and leading calls with medical monitors regarding new studies. This also includes recruiting physician providers to participate in the 24 hr/7 day a week coverage schedule.

CF TDNCC Clinical Studies Medical Director is a key member of the TDNCC leadership team working with the Co-Executive Directors to develop strategic initiatives and growth plans specific for the TDNCC to support a pipeline of CF multicenter studies and will work with the Co-Executive Directors and Business Operations Director to develop models for financial stewardship.

CF TDNCC Clinical Studies Medical Director will lead the inception submission and execution as a PI of grants to both the NIH and CFF for large multicenter studies to support the TDNCC and advance the mission of the TDN.

CF TDNCC Clinical Studies Medical Director will collaborate with managers directors and supervisors of the CF TDNCC to build a cohesive leadership team and will participate in the oversight of TDNCC studies.

CF TDNCC Clinical Studies Medical Director will partner with external investigators to ensure successful coordination of their studies within the CF TDNCC.

CF TDNCC Clinical Studies Medical Director will be a member of the advisor team for the TDNs Industry Consulting Program evaluating clinical development packages and providing input on both scientific merit and feasibility.

CF TDNCC Clinical Studies Medical Director will serve on key advisory committees for the TDN including the Clinical Research Executive Committee.

CF TDNCC Clinical Studies Medical Director will report directly to both the Co-Executive Directors of the CF TDNCC and the appropriate Division Head of their clinical specialty.

The TDNCC Clinical Studies Medical Directors FTE is non-clinical time (20%-50% FTE) and time spent will be reflected by the Directors standard work schedule of meetings huddles and on or off-site presence with the TDNCC and other partners. Effort of support will be driven by existing grant support for the candidate. The goal of the position will be to gain more extramural funding thus transitioning to a lower effort provided.

Commit to and advocate for and support the Seattle Childrens Hospitals Leadership and Collaboration statement on Health Equity Becoming a leader in health equity and dismantling racist systems requires organization-wide commitment as well as action by individuals and teams. Accountability for making change lies with leaders but progress is not possible without the efforts of workforce and community members.

The successful candidate may have duties across multiple institutions as guided by their clinical division.

The Therapeutics Development Network (TDN) is a collaborative organization composed of specialists in CF clinical researchfrom a variety of disciplines and institutions including a central coordinating center (TDNCC) at Seattle Childrens Research Institute supporting clinical study development management and analysis in addition to eighty CF Therapeutic Development Centers (TDCs) responsible for the recruitment of study participants across TDN studies. The TDNCC oversees the timely and efficient implementation conduct and dissemination of results of multiple CFF NIH FDA and industry supported clinical trials and studies. The TDNCC actively works with companies to facilitate development of novel therapeutics in CF across multiple therapeutic classes including addressing increasingly complex clinical research design questions for the development of nucleic acid- based therapies anti-infectives anti-inflammatories and pulmonary therapies. The TDNCC is comprised of approximately 50 faculty and staff across multidisciplinary units including : Scientific and Network Partnerships Business Operations Clinical Studies Biostatistics and Clinical Data Management and Regulatory Affairs. The TDNCC Clinical Studies Medical Director will work closely with the TDNCC leadership team and CFF leadership to generate new study proposals and grant funding determine pipeline prioritization and assess the scientific merit and feasibility of new studies in addition to core responsibilities within the TDNCC.

Key job requirements include experience in grant submissions planning implementation and leading as a Principal Investigator of NIH R01 level funding (also acceptable R34/UG3/UH4) and/or CFF sponsored large multicenter clinical research studies in the field of CF.

Applicants must have a PhD in a relevant field or MD (or foreign equivalent). An MD/PhD (or foreign equivalent is also acceptable.

In order to be eligible for University sponsorship for an H-1B visa graduates of foreign (non-U.S.) medical schools must show successful completion of all 3 steps of the U.S. Medical Licensing Exam (USMLE) or equivalent as determined by the Secretary of Health and Human Services.